« Back
Home /
Recombinant Human VEGFR-1 (D5), soluble

Recombinant Human VEGFR-1 (D5), soluble

Manufacturer	Cell Sciences
Category	Oncology Neuroscience Protein Aggregation, Clearance & Misfolding Neural Development By Cell Type Blastoma Carcinoma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Peptides & Proteins Recombinant Proteins Cell Biology Cell Movement Cell Adhesion Cell Culture Cytokines Adenocarcinoma By Organ Bladder Cancer Colorectal Cancer Heart & Blood Cancer
Type	Proteins
Specific against	Human
Amount	5 ug
Host	Insect
Item no.	CS-CRF102A
Targets	VEGFA, FLT1, ABL1, KDR
eClass 6.1	34160400
eClass 9.0	42020190
Available
Biological Activity	Determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surface receptors. The ED50 for this effect is typically 10.0-30.0 ng/ml. The usable range is 5-50 ng/ml.
Description	Recombinant human soluble VEGFR1 Domain 1-5 is produced as a glycosylated monomeric protein. The soluble receptor protein contains only the first 5 extracellular domains (Met1-Asn562), which contain all the information necessary for high affinity ligand binding.
Endotoxin Level	< 0.1 ng/mg of VEGFR1
Formulation	Lyophilized without additives
Molecular Weight	72 kDa
Reconstitution	Centrifuge vial prior to opening. Soluble in water and most aqueous buffers. Add PBS or medium to the vial to fully solubilize the protein to a concentration not lower than 100 ng/ml.
Storage and Stability	Lyophilized protein is stable for 6 months at -20C to -80C. Store reconstituted protein in working aliquots at -20C. Avoid repeated freeze-thaw cycles.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.